Skip to Main Content

Paper Details

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Cell Rep
190
2016
BRCA, BRCA Wild-Type and Mutated Models, BRCA-mutated triple-negative breast cancer (TNBC) cells, BRCA1, BRCA1-mutated cell lines, CDK12, HR, PARP, PDX, TNBC, Triple-Negative Breast Cancer, cyclin-dependent kinases (CDKs) 1, 2, 5, and 9, dinaciclib, homologous recombination (HR)-deficient cancers, patient, poly(ADP-ribose), poly(ADP-ribose) polymerase, triple-negative breast cancer, tumor
Author NameAffiliation
José BaselgaMemorial Sloan Kettering Cancer Center
Andrea L RichardsonBrigham and Women's Hospital and Harvard Medical School
Alan D D'AndreaDepartment of Radiation Oncology and Center for DNA Damage and Repair, Dana-Farber Cancer Institute and Harvard Medical School, Dana-Farber Cancer Institute, Children's Hospital and Harvard Medical School
Alan D D'AndreaDepartment of Radiation Oncology and Center for DNA Damage and Repair, Dana-Farber Cancer Institute and Harvard Medical School, Dana-Farber Cancer Institute, Children's Hospital and Harvard Medical School
  • 1 - 4

Datasets

Release 1.2